Geneva, June 22 -- International Clinical Trials Registry received information related to the study (ChiCTR2600126555) titled 'A single-arm phase 2 clinical study of radiotherapy combined with sacituzumab tirumotecan and toripalimab for kidney-sparing treatment of localized high-risk upper urinary tract urothelial carcinoma' on June 11.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Sun Yat-sen University Cancer Center
Condition:
High-risk upper urinary tract urothelial carcinoma
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-06-11
Target Sample Size: Experimental group:20;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?pr...